Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Summary
This study is a prospective, randomized, parallel-controlled clinical trial. The primary objective is to evaluate the superiority and safety of nanocrystalline megestrol acetate in combination with standard therapy compared with standard therapy alone in improving appetite and body mass index (BMI) during treatment in patients with early-stage or locally advanced hepatocellular carcinoma at the cachexia stage.
Official title: A Prospective Clinical Study of Nanocrystalline Megestrol Acetate in Combination With Standard Therapy Versus Standard Therapy Alone for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
68
Start Date
2026-01-10
Completion Date
2027-12-31
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
Nanocrystalline Megestrol Acetate
Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.
Standard Antitumor Therapy
Standard Antitumor Therapy
Locations (1)
West China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China